Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

A. M. Pappas & Associates

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 19
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 18
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.05
Exits 8
Key employees 4

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Health Diagnostics
  • Biopharma
Summary

The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the Durham.

We also calculated 4 valuable employees in our database.

Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight CeNeRx BioPharma, Dynogen Pharmaceuticals, BrainCells. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the A. M. Pappas & Associates, startups are often financed by Wakefield Group, Sears Capital Management, Perseus-Soros Biopharmaceutical Fund. The meaningful sponsors for the fund in investment in the same round are Montreux Equity Partners, Domain Associates, Canaan Partners. In the next rounds fund is usually obtained by Pappas Ventures, Wellcome Trust, Varian.

The average startup value when the investment from A. M. Pappas & Associates is 10-50 millions dollars. Considering the real fund results, this Corporate Investor is 3 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2002. The fund is generally included in less than 2 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2013. Opposing the other organizations, this A. M. Pappas & Associates works on 21 percentage points more the average amount of lead investments.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of A. M. Pappas & Associates:
Typical Co-investors
A. M. Pappas & Associates is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after A. M. Pappas & Associates:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AlphaBlock Capital -
Beyond X Chiyoda, Japan
BW Offshore Norway, Oslo
Cartera de Inversiones CM Barcelona, Catalonia, Spain
CMT Digital Ventures LLC Chicago, Illinois, United States
Crystal-Optech China, Hangzhou, Zhejiang
DB Capital Ventures New York, New York, United States
Essel Finance India, Maharashtra, Mumbai
Federman Capital Boston, Massachusetts, United States
Future Invest China, Hangzhou, Zhejiang
Halliburton Energy Services Houston, Texas, United States
Health 100 China, Shanghai, Xuhui
HumanCo New York, New York, United States
Metallavon VC -
Old Ironsides Energy Boston, Massachusetts, United States
Securian Ventures Minnesota, Saint Paul, United States
Shenzhen Yizan Investment Management China, Guangdong, Shenzhen
Social Impact Fund -
Sunnybrook Research Institute -
Treasure Valley Angel Fund -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Biopharma
Biotechnology
Therapeutics
$15M29 Sep 2008 Cary, North Carolina, United States

Cerexa Inc.

Biotechnology
Health Care
Medical
Pharmaceutical
$50M23 Aug 2005 New York, New York, United States

BrainCells

Biotechnology
Health Care
Medical Device
$17M15 Jul 2005 San Diego, California, United States

Plexxikon

Biotechnology
Health Care
Medical
Pharmaceuticals
$46M26 May 2004 Berkeley, California, United States

Biotechnology
Health Care
Medical Device
$18M18 May 2004 Massachusetts, United States

Peninsula Pharmaceuticals

Biopharma
Biotechnology
Health Care
Health Diagnostics
Medical
$57M16 Jan 2004 California, United States

Selventa

Biotechnology
Health Care
Health Diagnostics
$6M08 Sep 2003 Cambridge, Massachusetts, United States

LipoScience

Biotechnology
Health Care
Health Diagnostics
Life Science
$15M07 Aug 2003 Raleigh, North Carolina, United States

Emerald BioAgriculture Corporation

Agriculture
Biopharma
Biotechnology
$6M29 Jan 2003 Michigan, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent A. M. Pappas & Associates?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: